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Abstract: Circulating platelets (PLTs) are able to affect glioblastoma (GBM) microenvironment by 
supplying oncopromoter and pro-angiogenic factors. Among these mediators, sphingosine-1-
phophate (S1P) has emerged as a potent bioactive lipid enhancing cell proliferation and survival. 
Here, we investigated the effect of “tumor education”, characterizing PLTs from GBM patients in 
terms of activation state, protein content, and pro-angiogenic potential. PLTs from healthy donors 
(HD-PLTs) and GBM patients (GBM-PLTs) were collected, activated, and analyzed by flow 
cytometry, immunofluorescence, and Western blotting. To assess the pro-angiogenic contribution 
of GBM-PLTs, a functional cord formation assay was performed on GBM endothelial cells (GECs) 
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with PLT-releasate. GBM-PLTs expressed higher positivity for P-selectin compared to HD-PLTs, 
both in basal conditions and after stimulation with adenosine triphosphate (ADP) and thrombin 
receptor activating peptide (TRAP). PLTs showed higher expression of VEGFR-1, VEGFR-2, VWF, 
S1P, S1PR1, SphK1, and SPNS. Interestingly, increased concentrations of VEGF and its receptors 
VEGFR1 and VEGFR2, VWF, and S1P were found in GBM-PLT-releasate with respect to HD-PLTs. 
Finally, GBM-PLT-releasate showed a pro-angiogenic effect on GECs, increasing the vascular 
network’s complexity. Overall, our results demonstrated the contribution of PLTs to GBM 
angiogenesis and aggressiveness, advancing the potential of an anti-PLT therapy and the usefulness 
of PLT cargo as predictive and monitoring biomarkers. 
Keywords: glioblastoma; platelets; sphingosine-1-phosphate; angiogenesis 
 
1. Introduction 
Glioblastoma (GBM) is the most frequent and deadliest primary human brain tumor, as patients 
rarely survive beyond 14 months, with a 5-year survival rate of around 5% [1]. GBM has virtually no 
effective treatment, representing a considerable therapeutic challenge for which novel paradigms 
should be considered. GBM is characterized by rapid progression, invasiveness, intense angiogenesis, 
resistance to radio- and chemotherapies, and a high frequency of relapse. As defined in the Stupp 
protocol, the current GBM standard of care includes surgical resection followed by radiotherapy with 
concomitant and adjuvant temozolomide (TMZ) [2]. Despite these aggressive approaches, most 
patients suffer recurrence after less than one year. The therapy resistance of GBM is mostly due to a 
subpopulation of tumorigenic stem-like cells, known as GBM stem cells (GSCs), which are self-
renewing, pluripotent, highly proliferative, and genetically unstable. GSCs hierarchically drive 
tumor progression and recurrence [3]. Upon pro-tumorigenic stimuli, GSCs can transdifferentiate 
into GBM endothelial cells (GECs), to directly contribute to the perivascular niche [4]. GECs trigger 
pro-angiogenic factor production and the formation of abnormal blood vessels to sustain GBM 
growth [5]. Importantly, transdifferentiated GECs can also acquire resistance and genetic mutations 
[6]. The communication between GECs and GSCs is a two-way exchange in which, aside from direct 
cell–cell communication, they can also bidirectionally exchange signals, including nucleic acids, 
proteins, and metabolites, thereby creating a permissive tumor microenvironment (TME). Among 
TME signals, bioactive membrane lipids, such as sphingolipids, may play an important role in 
promoting tumorigenesis and cancer malignancy. Indeed, sphingosine-1-phosphate (S1P) is able to 
stimulate cellular processes strictly related to cancer, such as proliferation, invasion, survival, and 
angiogenesis [7]. The biosynthesis of S1P occurs during complex sphingolipid catabolism via the 
conversion of ceramide (Cer) to sphingosine (Sph), which is then phosphorylated to S1P by Sph 
kinases (SphK1/2) [8]. The secretion of S1P out of the cell is mediated by the transporter spinster 
homology protein 2 (Spns2), which belongs to the major facilitator superfamily (MFS). As an 
extracellular signal, S1P exerts its effects by binding to five specific G protein-coupled receptors 
(S1PR1–5) located in the plasma membrane [8]. S1P also plays pleiotropic functions in gliomagenesis. 
In particular, rapidly proliferating GSCs exhibit fast conversion of Sph to S1P, perform rapid 
degradation of newly synthesized Cer, and release a 10-fold higher amount of S1P in the extracellular 
milieu compared to slow-proliferating GSCs [9]. Interestingly, previous studies reported that GECs 
are also well equipped to produce and release S1P and, when co-cultured with GBM cells, GECs 
exhibited increased SphK2 expression and activity, with significant S1P secretion enhancement. In 
turn, in an autocrine/paracrine manner, extracellular S1P stimulates GBM cell growth and GEC 
migration and tubule formation in an S1PR1/S1PR3-dependent trend [10]. In GBM, GECs undergo 
activation, thereby causing an increased exposition of von Willebrand Factor (VWF) on their surface. 
VWF, a multimeric adhesive glycoprotein, is mainly secreted from Weibel Palade Bodies (WPBs) of 
GECs. Increased plasma levels of VWF antigen (VWF:Ag) have been found in GBM patients, with 
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higher VWF plasma levels correlating with shorter survival, rendering VWF:Ag levels a putative 
circulating prognostic factor [11]. The mechanisms involved in VWF exocytosis are poorly 
understood, but recent observations revealed that S1P is able to trigger increased WPB secretion and 
endothelial barrier disruption [12]. Moreover, VWF may protect cancer cells from immune cells and 
mediate platelet (PLT) adhesion to vascular damage sites [13]. At the site of injury, PLTs degranulate, 
releasing pro-angiogenic factors such as VWF, vascular endothelial growth factor (VEGF), and S1P. 
Interestingly, PLTs were originally suggested to be the prime source of plasmatic S1P because of their 
high SphK activity [14] and lack of S1P lyase [15]. Thus, it is reasonable to consider PLTs as functional 
circulating carriers of S1P [16–18] acting in a dual process: (i) accumulating huge reservoirs of 
biomolecules, sequestering tumor-derived factors/signals (e.g., growth factors, cytokines, nucleic 
acids), and thus developing into “tumor-educated” PLTs (TEPs) [19], and (ii) releasing microparticles 
shuttled to tumors to regulate both anti- and pro-tumorigenic gene expression programs. Previous 
results reported that PLTs from GBM patients showed significantly elevated concentrations of VEGF 
when compared to healthy subjects, with a negative correlation between PLT-released VEGF and 
patient prognosis [20]. In this study, we present our preliminary data on PLT characterization from 
GBM patients in terms of activation state, protein content, and pro-angiogenic effects, in order to 
investigate their role as pro-tumoral carriers. 
2. Materials and Methods 
2.1. Patient Recruitment 
GBM patients (n = 10) were recruited during hospitalization at the Neurosurgery Unit of 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico. The Institutional Review Board 
approved the protocol and all patients provided informed consent. All research was performed in 
accordance with relevant guidelines and regulations. The inclusion criteria for patient enrolment 
were as follows: (i) aged between 18–75 years; (ii) Karnofsky performance status (KPS) >70; (iii) 
confirmed diagnosis of GBM; (iv) informed consent signed. The exclusion criteria were as follows: (i) 
presence of another primary tumor or proven metastasis; (ii) concomitant life-threatening disease; 
(iii) pathology affecting the blood circulation and the coagulation system. Demographic, clinical, and 
molecular characteristics of the patients are listed in Table 1. 
Table 1. Demographic, clinical, and molecular parameters of the patient cohort. 
Patient 
ID 
Sex Age Diagnosis KPS (%) IDH MGMT (%) Ki-67 (%)  Tumor Region 
HD01 F 28 N/A - - - - - 
HD02 F 39 N/A - - - - - 
HD03 M 37 N/A - - - - - 
HD04 F 53 N/A - - - - - 
Poli 201 F 60 GBM 80 w/t 2 20 PO sx 
Poli 202 F 68 GBM 80 w/t 34 70 T dx 
Poli 203 M 69 GBM 80 w/t 25 40 TP dx 
Poli 204 M 67 GBM 80 w/t 8 20 TP dx 
Poli 205 M 49 GBM 90 w/t 32 12 PO dx 
Poli 206 M 73 GBM 70 w/t 16 25 PO dx 
M: male, F: female; KPS: Karnofsky performance status; IDH: isocitrate dehydrogenase; MGMT: O 
(6)-methylguanine-DNA methyltransferase; PO: parietal–occipital region, T: temporal region, TP: 
temporal–parietal region. 
2.2. Tumor Sample Collection and Processing 
Tissue samples from patients who underwent surgical resection of GBM at the Neurosurgery 
Unit of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico were collected. Tumor 
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specimens were washed in D-PBS (Euroclone, Milan, Italy) and suspended in DMEM/F12 
(ThermoFisher, Waltham, Massachusetts, USA) containing 1% penicillin/streptomycin. At the 
Laboratory of Experimental Neurosurgery and Cell Therapy, tissues were processed by fine mincing 
with a surgical scalpel in D-PBS and antibiotic solution. After shredding, samples were enzymatically 
digested with 0.625 Wu/mL Liberase Blendzyme 2 (Roche, Mannheim, Germany) for 1 h at 37 °C 
[5,21]. 
2.3. GEC Isolation and Characterization 
The tissue suspension was filtered with a 0.22 µm pore-size filter to obtain a monocellular cell 
suspension. Cells were plated into a 25 cm2 flask coated with bovine type I collagen (BD Biosciences, 
Milan, Italy) and cultured in endothelial proliferation medium, EndoPM, at 37 °C in 5% CO2 and 5% 
O2, according to published protocols [5,21,22], in order to isolate the endothelial cell population (ECs). 
The media was changed 1–2 times a week and passaged at a split ratio of 1:4 every 14 days [5,9]. 
2.4. Blood Sample Collection 
Blood samples from GBM patients (n = 6) were collected from patients undergoing surgery for 
GBM resection. The blood was withdrawn in the presence of 3.2% Na-citrate the day before surgery 
after signed consent. Blood from healthy donors (HD, n = 4) was also obtained after informed consent. 
The enrolled subjects did not take aspirin or other nonsteroidal anti-inflammatory drugs for at least 
10 days before the blood draw [20]. 
2.5. PLT Preparation and Stimulation 
The whole blood was centrifuged at 150× g for 15 min to obtain platelet-rich plasma (PRP). The 
PRP was transferred into a new tube with ACD anticoagulant buffer 1:10 (6.25 g sodium citrate, 3.1 
g citric acid anhydrous, 3.4 g glucose, pH 6.5 in 250 mL H2O), centrifuged (600× g, 5 min) and the 
resulting platelet-poor plasma (PPP) was stored at −20 °C. PLTs were then washed twice with HEPES-
Tyrode’s buffer (134 mM sodium chloride, 12 mM sodium bicarbonate, 2.9 mM potassium chloride, 
0.34 mM sodium phosphate monobasic, 1 mM magnesium chloride, 5 mM HEPES, 5 mM glucose, 
1% BSA, pH 7.4), counted, and resuspended to produce a final concentration of 3 × 108 platelets/mL. 
The PLTs were then incubated with adenosine diphosphate (ADP) at a concentration of 10 µM or 
thrombin receptor activating peptide (TRAP) at a concentration of 5 μM for 20 min at 37 °C to induce 
stimulation. Finally, the PLTs were centrifuged at 300× g for 5 min, and the supernatant containing 
the stimulated PLT-releasate was stored at −20 °C [20]. 
2.6. Flow Cytometry Analysis 
Stimulated and non-stimulated PLTs (S-PLTs and NS-PLTs, respectively) were analyzed by flow 
cytometry for the expression of CD62P, a marker of activated PLTs. After incubation with FITC-
conjugated CD62P, analysis was conducted using FACS Canto II flow cytometer and 
FACSDivasoftware (BD Bioscience, version 5.0) [20]. Forward- versus side-scatter (FSC-A vs. SSC-A) 
gating was used to identify intact PLTs based on size and granularity. 
2.7. Immunofluorescence Analysis 
NS-HD-PLTs, NS-GBM-PLTs, and S-GBM-PLTs (stimulated with thrombin at 0.1 U/mL, as 
previously described [20]) from 3 GBM patients and 2 age- and gender-matched HDs were seeded 
(1× 106 PLTs/well) onto a µ-plate 96-well Black for optimized fluorescence-based imaging of the fixed 
cells. The PLTs were fixed in 8% paraformaldehyde 8for 20 min at room temperature (RT), washed 
twice with D-PBS, and incubated with 0.1 M glycine to quench autofluorescence. Then, the PLTs were 
treated with PBS + 0.25% Triton X-100 to permeabilize the cell membranes and then blocked in PBS + 
5% BSA for 30 min at RT. Incubation with primary antibodies (AB-I) diluted in blocking buffer was 
performed overnight at 4 °C. The following AB-I were used: anti-VEGFR1 (ThermoFisher), anti- 
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VEGFR2 (Abcam, Cambridge, UK), anti-VWF (ThermoFisher), anti-S1P (Sonepcizumab, Creative 
Biolabs, Shirley, New York, USA), anti-S1PR1 (Abcam), anti-SphK1 (Abcam), anti-SPNS (Abcam), 
anti-phalloidin, and anti-P-selectin (SantaCruz Technology). The following day, the AB-I were 
removed and, after three washes with PBS + 0.1% BSA, AB-II were added for 1h at RT [5,21,22]. 
Immunolabeling was acquired using a high-resolution Nikon Ti spinning disk microscope (Nikon 
Instruments, Florence, Italy) equipped with a CREST-optics spinning disk head, a VCS structure 
illumination module for super-resolution (CREST-Optics, Rome, Italy), and Andor cameras for 
resolution (Andor Zyla, Andor Technology, Oxford Instruments, Oxford, UK) and quantum 
efficiency (Andor Technology, Oxford Instruments, Oxford, UK). A TIRF 100× objective (NA 1.49) 
(Nikon Instruments, Florence, Italy) was used to acquire both spinning disk confocal images (over a 
3-micron Z-stack with a 0.2-micron Z-step) and for structure illumination super-resolution 
acquisition. The Richardson–Lucy 3D deconvolution algorithm (NIS-Elements V.5.2.11) was used to 
deconvolve the spinning disk confocal images, whereas specific VCS-Studio algorithms (CREST 
Optics, Rome, Italy) were employed for correct structure illumination reconstruction. High resolution 
imaging was performed on all stained wells using the whole-well approach though large-mosaic 
rendering during high-magnification acquisition in order to obtain a complete field of view (FOV) of 
the whole well for each instance of double-IF labeling. Acquisitions of all wells and different labeling 
instances were performed using the same experimental parameters, the same set-up with similar LED 
excitation power (10–20% for all LED lines at 470, 555, and 640 nm), and the same detection 
parameters in terms of the spinning disk wavelength band-filters and EM-CCD camera read-out rates 
(50 msec exposure plus 100 EM-gain at 30 MHz frequency); processing, segmentation, and image 
quantifications were conducted simultaneously on all acquired FOVs. The processed images were 
quantified using ad-hoc prepared pipelines of image segmentation and quantification, employing 
both GA2 and GA3 modules of NS-Elements digital imaging analysis software (Nikon Instruments, 
Florence, Italy). In detail, the platelets were morphologically segmented and labeling positivity was 
used to both quantify the signal intensity and classify the objects for single and double labeling. 
Quantified image analysis parameters from all FOVS were subsequently plotted on the same graphs, 
thus allowing observation of the homogeneity and data distribution from the complete set of samples 
used for the IF assay. 
2.8. Western Blot 
A Western blot was performed to assess the concentration of pro-angiogenic proteins in the PLT-
releasate of 4 HDs and 6 GBMs. Specifically, the protein amount was measured by Pierce Detergent 
Compatible Bradford Assay Kit (Thermo Fisher Scientific). An equal amount of protein (50 µg) was 
separated in Bolt 10% Bis-Tris Plus Gel (Thermo Fisher Scientific) in a Mini Gel Tank (Thermo Fisher 
Scientific) and transferred onto nitrocellulose iBlot 2 Transfer Stacks using the iBlot 2 Dry Blotting 
System (Thermo Fisher Scientific). After transfer, the membrane was blocked in Tris-buffered 
saline/Tween 20 + 5% milk solution and incubated separately with anti-GAPDH (SantaCruz 
Biotechnology), anti-VEGF (Abcam), anti-VEGFR2 (Abcam), anti-VWF (Thermo Fisher Scientific), or 
anti-S1P (Sonepcizumab, Creative Biolabs) overnight at 4 °C. After incubation with HRP-labeled 
secondary antibody (Invitrogen, Carlsbad, California, USA), the protein bands were scanned using 
SuperSignal West Femto PLUS Chemiluminescent Substrate (Thermo Fisher Scientific) and detected 
by iBright5000 ChemiDoc XRSþ (Thermo Fisher Scientific). Densitometric analyses were performed 
using ImageJ [21]. 
2.9. Tube-Formation Assay 
To assess the effect of PLT-releasate on angiogenesis, GECs (1 × 104/well) were seeded onto a μ-
plate angiogenesis 96-well (Ibidi), which was pre-coated with 12.5 mg/mL Matrigel (BD Bioscience) 
and cultured at 37 °C in 5% CO2 and 5% O2 in the presence or absence of PLT-releasate diluted at 1:10 
in EndoPM. The GECs cultured in EndoPM + HEPES-Tyrode buffer (1:10) were used as the untreated 
control, referred to as the basal medium (BM). Cord formation was monitored with an inverted 
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Eclipse Ti-E microscope (Nikon Instruments, Florence, Italy), which was equipped with a high 
resolution cSMOS camera (Andor Zyla, Andor Technology, Belfast, UK) and NIS_Elements 4.51 
software, using differential interference contrast (DIC). After 24 h of incubation, five random images 
were acquired and analyzed using the “Angiogenesis Analyzer” plugin in ImageJ [5,21,22]. 
2.10. Statistical Analysis 
All analyses were performed with GraphPad (Prism 8). Cytofluorimetric parameters were 
analyzed using the Mann–Whitney U test for independent samples (HD vs. GBM) and by the 
Kruskall–Wallis test for the analysis of cord formation (BM and PLT-releasate from HD- and GBM-
PLTs). When significant differences were detected, Dunnet post-hoc comparisons against the control 
group were made. Differences were considered statistically significant at p < 0.05. Values were 
expressed as the mean ± SD of at least 3 independent experiments. 
3. Results 
3.1. GBM-PLTs Show an Activated State 
Flowcytometric analyses were performed to determine the state of activation of HD- and GBM-
PLTs. PLTs isolated from GBM patients expressed higher levels of CD62P (75.6% ± 6%) compared to 
HD-PLTs (33.7% ± 4%). When GBM-PLTs were treated with 10 µM ADP, we noticed that CD62P 
expression did not change in the HD-PLTs (35.4% ± 5%), and only a slight increase was detected in 
the GBM-PLTs (81.6% ± 7%) (Figure 1A). Contrarily, after the stimulation of PLTs with TRAP, which 
is considered to be the strongest platelet activator via protease-activated receptors, HD-PLTs reached 
a CD62P-positivity percentage of 73.2% ± 7%, whereas GBM-PLT stimulation resulted in an almost 
total activation of 91.1% ± 8%. Representative flow cytometric plots for the detection of platelet 
activation and CD62P positivity quantification are reported in in Figure1B–D. Notably, the blue cells 
represent PLTs with compromised scatter, indicating damaged PLTs and cell debris; these were 
excluded from the analysis for CD62P-positivity. 
 
 
Figure 1. Glioblastoma platelets (GBM-PLTs) show a higher activated state compared to healthy 
donor (HD)-PLTs. (A) Representative dot plots from flow cytometry acquisition performed on HD- 
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and GBM-PLTs under basal conditions and after stimulation with 10 µM adenosine triphosphate 
(ADP) and 5 µM thrombin receptor activated peptide (TRAP). NS: not stimulated. Plot 1 represents 
the first analysis performed according to side-scatter (SSC-A) and forward-scatter (FSC-A); blue cells 
represent PLTs with compromised scatter, i.e., cell debris, whereas red cells represent intact PLTs, 
which were further analyzed. In Plot 2, the red cells represent CD62P-negative PLTs, while the green 
cells are CD62P-positive. CD62P-expression levels were expressed as percentages and indicated in 
each box. (B–D) Platelet counts and platelet activation were determined by flow citometry analysis 
for CD62P in HD- and GBM-PLTs in the resting state (B) (NS) after ADP (C) and TRAP (D) 
stimulation. The expression of CD62P was significantly higher in GBM-PLTs both under basal 
conditions and after stimulation with ADP and TRAP. * p < 0.05, ** p < 0.01 versus healthy donors 
(HD). 
3.2. GBM-PLTs Express and Release More Pro-Angiogenic and Pro-Tumoral Markers than HD-PLTs 
Immunofluorescence revealed intense positivity of GBM-PLTs to pro-tumoral and pro-
angiogenic factors compared to HD-PLTs. GBM-PLTs showed higher expression of VEGF- signaling, 
VWF, and P-selectin, which are markers of angiogenesis and endothelial activation. Higher 
expression levels of both VEGFR1 and VEGFR2 were detected in GBM-PLTs compared to HD-PLTs; 
interestingly, after stimulation, the localization of VEGF receptors moved from the cytoplasm to the 
cell membrane (Figure 2, column A). Indeed, the quantification in the field of view (FOV) of the mean 
fluorescence intensity (MFI) for VEGFR1 showed a significantly more intense signal in GBM-PLTs 
compared to HD-PLTs, with decreased signal intensity in GBM-PLTs after stimulation (Figure 3A). 
In turn, VEGFR1 MFI was significantly higher in the releasate in S-GBM-PLTs with respect to NS-
GBM- and HD-PLTs (Figure 3B). The same trend was also observed for VEGFR2, where PLTs showed 
a significantly more intense signal in GBM-PLTs in both the resting and stimulated states compared 
to HDs (Figure 3C). Like VEGFR1, the VEGFR2 MFI was also significantly higher after PLT 
stimulation in GBM patients compared to HD subjects (Figure 3D). This condition may be explained 
by the fact that after activation, PLTs were more prone to receive extracellular signals and to initiate 
intracellular signaling pathways. The immunolabeling for VWF revealed a higher positivity in GBM-
PLTs than in HD-PLTs, as well as a definite localization of VWF in the PLT membrane. Interestingly, 
S-GBM-PLTs showed the ability to form VWF fibers, a widely recognized marker of activation (Figure 
2, column B). The quantification of the MFI revealed that NS-GBM-PLTs expressed more intra-PLT 
VWF (Figure 3E), while a significantly more intense signal was detected in S-GBM-PLTs after 
stimulation compared to HDs (Figure 3F). A similar tendency was detected for S1P-related factors, 
such as S1P, Sphk1, S1PR1, and SPNS, both under basal conditions and after stimulation. Indeed, 
especially for S1P, a strong signal was visible inside GBM-PLTs in the NS condition together with 
S1PR1 (Figure 2, column C, Figure 3G–I). When stimulated, GBM-PLTs released S1P in the 
extracellular milieu, thereby enhancing S1P labeling outside PLTs (Figure 2, column C, Figure 3H). 
Similar behavior was shown by S1PR1, which was localized in the cell membrane in NS-GBM-PLTs 
and released after activation, probably via microvescicle-mediated secretion (Figure 2, column C, 
Figure 3I). For SphK1 and SPNS, enhanced fluorescence was observed after stimulation of GBM-PLTs 
(Figure 2, column D and column E, respectively), both in terms of intra-PLTs and the releasate. The 
quantification of MFI in Sphk1-positive PLTs positive revealed similar expression levels in HDs 
compared to GBM patients, both under the resting and stimulated conditions (Figure 3J). 
Interestingly, GBM-PLTs showed greater expression for SPNS compared to HD-PLTs (Figure 2, 
column E); this increment was statistically significant for the stimulated PLTs (Figure 3K). The 
immunopositivity for P-selectin showed a significant increment in GBM-PLTs after stimulation 
compared to HD-PLTs (Figure 3L). 
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Figure 2. Localization of pro-angiogenic and pro-tumoral molecules in GBM-PLTs and HD-PLTs by 
immunophenotypic analysis. Representative images of immunofluorescence analyses conducted on 
non-stimulated (NS)-HD-PLTs, NS-GBM-PLTs, and stimulated (S)-GBM-PLTs. Immunolabeling was 
performed for (A) VEGFR1 and VEGFR2, (B) P-selectin and VWF, (C) S1PR1 and S1P, (D) SphK1, (E) 
SPNS and Phalloidin. The white box contains an enlargement of the image. Scale bar: 10 μm. 
 
Figure 3. GBM-PLTs expressed and released pro-angiogenic and pro-tumoral molecules compared to 
HD-PLTs. Data from (A)VEGFR1, (C)VEGFR2, (E) VWF, (G) S1P, (I) S1PR1, (J) SPhK1, (K) SPNS, and 
(L) P-selectin labelings of PLTs from HD and GBM patients in non-stimulated (NS-) and stimulated 
(S-) conditions. Image analysis through ad-hoc-created pipeline of binary segmentation and object 
quantification to detect and analyze the specific mean fluorescence intensity (MFI) of PLTs in an 18-
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mm2 field of view (FOV). The number of spots of (B) VEGFR1, (D) VEGFR2, (F)VWF, and (H) S1P 
were detected and counted with the same pipeline of binary segmentation in the PLT-releasate. * p < 
0.05, ** p < 0.01, *** p < 0.001 versus healthy donors (HD). 
3.3. Protein Content in GBM-PLTs  
Quantification of protein content revealed that, when normalized to the PLT count, a greater 
amount of protein was present in GBM-PLTs compared to HD-PLTs (Figure 4A), indicating the 
ability of GBM-PLTs to act as active carriers of potentially tumor-derived oncopromoter mediators. 
The investigation of the expression of pro-angiogenic factor by Western blotting exposed GBM-PLTs 
to contain higher concentrations of VEGF, VEGFR2, VWF, and S1P (Figure 4B). The quantification of 
densitometry revealed that, when normalized to GAPDH expression, VEGF, VEGFR2, VWF, and S1P 
were 2.5-, 2.1-, 2.4-, and 5.8-fold higher, respectively, in GBM-PLTs than in HD-PLTs (Figure 4C). 
 
 
Figure 4. Pro-angiogenic and pro-tumoral protein contents in GBM- and HD-PLTs. (A) Quantification 
of HD- and GBM-PLT protein contents. Data are shown as mean  SD of all samples analyzed, 
normalized to the PLT count. (B) Densitometric quantification of the protein expressions of VEGF, 
VEGFR2, VWF, and S1P in all of the analyzed HD- and GBM-PLTs. Data were normalized to GAPDH 
expression, used as an endogenous control, and reported as the mean  SD. (C) Representative images 
of Western blot analysis for the assessment of protein concentrations of VEGF, VEGR2, VWF, and S1P 
in PLT-releasate from 2 HD-PLTs and 4 GBM-PLTs. Notably, the graph in Figure 4C reports 
densitometric data versus GAPDH. * p < 0.05, ** p < 0.01, *** p < 0.001 versus healthy donors (HD). 
3.4. GBM-PLT-Releasate Enhances Angiogenesis in GECs 
The tube-like structure formation displayed the pro-angiogenic effect of the releasate of GBM-
PLTs on GECs. Indeed, in the presence of GBM-PLT-releasate, GECs increased the number of “vessel-
like” cords, segments, and meshes, thus creating a more complex vascular network. On the contrary, 
only a slight effect was observed when GECs were cultured in the presence of HD-PLT-releasate 
(Figure 5). 
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Figure 5. GBM-PLT-releasate strongly induced GBM endothelial cell (GEC) cord formation. (A) 
Representative images of GECs cultured for 24 h in Matrigel with PLT-releasate from HD- and GBM-
PLTs for 24 h. (B) Quantification of number of master segment meshes and total tube length measured 
using the Angiogenesis Analyzer plugin in ImageJ. Data are the mean  SD of at least 3 experiments 
in triplicate. * p < 0.05 versus basal medium (BM); # p < 0.05 versus HD-PLT-releasate. 
4. Discussion 
Over the last few decades, an increasing number of clinical and experimental studies 
investigated the association between PLTs and tumorigenesis, as well as drug resistance. Indeed, 
PLTs may serve as circulating carriers of pro-tumor factors, thus acting systemically and locally in a 
beneficial manner regarding tumor progression and stimulating tumors to be resistant to therapies 
[23]. For this reason, unraveling the functional contribution of PLTs in tumor angiogenesis and 
growth may potentially provide better strategies for cancer treatment [24]. In this work, we 
hypothesized that the highly intense hypervascularization of GBM contributes to an overexposure of 
VWF on the GEC surface, thereby determining the massive recruitment and activation of circulating 
PLTs. At the site of injury, tumor cell-induced platelet activation (TCIPA) is characterized by PLT 
aggregation, adhesion, and a strong increase of PLT-derived pro-angiogenic factors [25]. PLTs are 
activated by their essential pathways, such as thromboxane (TX)-A2, glycoprotein (GP)-Ib-IX, ADP, 
and GPIIb/IIIa [26], leading to a dramatic increase in PLT-activation markers, such as P-selectin 
(CD62P) and angiogenesis mediators. Literature evidence reported that PLTs from breast cancer 
patients contained significantly higher levels of VEGF, angiopoietin-1, and P-selectin compared to 
normal controls [27]; similarly, the concentrations of VEGF and platelet-derived growth factor 
(PDGF) were increased in colorectal cancer patients compared to controls [28], as well as in GBM 
patients [20]. In this study, we asked whether soluble factors released from activated TEPs could 
influence GBM aggressiveness, thereby ensuring growth factor bioavailability and promoting 
angiogenesis and thus shifting the tumor microenvironment in favor of cancer progression. Our 
results revealed that GBM-PLTs present an activated state, proved by the expression of P-selectin, 
compared to HD-PLTs. This activation status increases after in vitro stimulation, which mimics the 
typical TCIPA occurring in GBM and, in particular, in the GBM vascular network. TCIPA induces 
the fine mechanism of “tumor education”, by which PLTs fill up with pro-angiogenic factors, which 
are in turn secreted after TCIPA in a self-sustaining vicious cycle. Immunolabeling showed the 
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different activation states of HD- and GBM-PLTs, revealing a higher expression of activation markers, 
pro-angiogenic, and oncopromoter factors, such as P-selectin, VEGFR1, VEGFR2, VWF, S1P, its 
receptor S1PR1, the kinase SPhK1, and the transporter, SPNS2. Likewise, the investigation of PLT-
releasate after induced activation revealed that GBM-PLTs carried higher amount of the same 
oncopromoter mediators, such as S1P, VWF, VEGF, and VEGFR2. PLTs are able to produce and store 
large amounts of S1P, and the biosynthetic process guided by SphKs represents the major source of 
S1P production [29]. However, although they possess high SphK activity, PLTs lack the de novo 
sphingolipid biosynthesis necessary to provide substrates. Interestingly, PLTs are able to incorporate 
extracellular 3H-labeled Sph much faster than human megakaryoblastic cells, and rapidly convert it 
to S1P [30]. Therefore, the high concentration of S1P into PLTs is determined by two sources: 
generation by extracellular Sph incorporation and phosphorylation by intraplatelet SphKs, and 
storage during PLT biogenesis from megakaryocytes (MKs), as SphK messenger RNA (mRNA) was 
reported to be the major Sphk transcript expressed in MKs [14]. Furthermore, it was demonstrated 
that the serum level of S1P increased about 2-fold after clot formation, suggesting that PLT 
aggregation led to S1P release [31]. Indeed, experimental evidence reported that PLT activation could 
strongly augment local S1P concentration, potentially engaging receptors or shifting the balance 
regarding their activation. The secretion of S1P in the extracellular milieu may be mediated both by 
the S1P transporter SPNS and PLT degranulation. Therefore, the increase in S1P concentration in 
stimulated PLTs as well as in PLT-releasate perfectly matches with the higher activation status and 
with the overexpression of SPNS. Thanks to the expression of S1P receptors on vascular smooth 
muscle cells, the increase in the S1P concentration plays a key role in endothelial repair by switching 
on the angiogenic mechanism. Similarly, in GBM, the local increase in S1P by PLT release after 
TCIPA, exerts a pro-angiogenic stimuli for neovascularization, thereby allowing the formation of 
pathological blood vessels which provide nutrients and oxygen for tumor growth. From this 
evidence, it is reasonable to explain the higher positivity of Sphk1 and S1PR1 in activated GBM-PLTs 
compared HDs, therefore a key contribution of PLT-derived S1P in GBM progression can be 
hypothesized. Likewise, VEGF and its signaling pathway are the most important positive regulators 
of angiogenesis, acting as an effective mitogen and survival factor for GECs and impacting blood 
vessel integrity and permeability. The high expression of VEGF and its receptors was widely 
demonstrated in GBM and many other forms of cancer, leading to a monoclonal antibody to be 
developed against VEGF, bevacizumab (Avastin® ), which is administered for colorectal cancer, 
metastatic breast cancer, and non-small cell lung cancer, as well as for relapsed forms of GBM [32]. It 
was demonstrated that the local high concentration of VEGF was supported by PLT contribution, as 
PLTs store VEGF in their α-granuli, which are released after TCIPA. We previously reported that the 
intraplatelet concentrations of VEGF were significantly elevated in primary GBM, and ADP- and 
thrombin-stimulation led to high levels of VEGF in the PLT-releasate, which we found to be directly 
correlated with patient survival in our study group [20]. It is now clear how essential this much higher 
expression of VEGF and VEGFR1/2 in GBM-PLT is in terms of VEGF carrying, both at the local and 
systemic levels. In GBM, VEGF-mediated neovascularization leads to the formation of fenestrated 
blood vessels, subsequently producing a loss of integrity and increased permeability. The strong 
activation of GECs causes exposition on their surfaces for VWF, which mediates PLT recruitment, 
aggregation, and activation. We previously reported higher plasma levels of VWF antigen (VWF:Ag) 
in GBM patients compared to patients with benign lesions, showing that higher VWF plasma levels 
were correlated with shorter survival, rendering VWF:Ag levels a putative circulating prognostic 
factor [11]. In this work, we demonstrated that VWF is a component of PLT cargo and is released in 
the GBM tumor mass after TCIPA, thereby supporting a self-sustaining vicious cycle. Finally, we 
tested the effect of this enriched PLT-releasate on GEC angiogenic potential via the tube-formation 
assay. The results revealed a strong effect of PLT content on GECs, which managed to form a complex 
vascular network with an increased number of cords and meshes. 
Taken together, our findings support the concept of a self-sustaining vicious cycle, in which 
TEPs are considered to be local and systemic responders to the presence of cancer, sequestering, 
carrying, and releasing tumor-derived biomolecules as RNA, proteins, and especially bioactive lipids, 
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such as S1P, thereby supporting tumor progression. This work investigated the role of sphingolipid 
signaling/metabolism in gliomagenesis, filling the gap between local and systemic events and 
changing the vision of GBM from a localized tumor which is confined to the brain to a systemic 
pathology, in which many different organs and cell subpopulations contribute via S1P-orchestated 
mechanisms (Figure 6). 
 
Figure 6. The concert between GBM stem cells (GSCs), GECs, PLTs, and tumor microenvironment 
(TME), orchestrated by S1P. A schematic representation of the concept of a self-sustaining vicious 
cycle, in which, in “CONCERT”, S1P plays the master regulator role, acting similar to an “orchestra’s” 
conductor, telling the ”musicians”, i.e., GSCs, GECs, PLTs, and VWF, who and when should play in 
the complex, multi-factorial “GBM symphony”. This theory fills the gap between the local and 
systemic key events, changing the vision of GBM from a localized tumor confined to the brain to a 
systemic pathology, in which many different organs and cell subpopulations give their contribution 
via S1P-orchestated mechanisms. 
5. Conclusion 
GBM is the deadliest primary brain cancer in adults. Despite the development of different 
therapeutic approaches, limited progress has been made to improve the poor patient overall survival, 
suggesting that novel paradigms should be considered. Drug resistance also remains a problematic 
challenge for both scientists and clinicians. Due to their strong association with tumors via tumor 
education and TCIPA mechanisms, activated PLTs with their oncopromoter cargo potentiate 
chemoresistance of cancer cells through the regulation of tumor growth and angiogenesis. Therefore, 
targeting the two-way signal exchange between tumors and PLTs and, more specifically, targeting 
PLT-originated growth factors may represent a promising approach to enhance the sensitivity of 
tumors to therapy. Finally, PLTs may be used as easily accessible, non-invasive biomarkers to predict 
the response to therapy and monitor tumor progression and eventual relapses via a personalized 
medicine strategy. 
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